ERBB2 and breast cancer: The effect was stronger in HCC1954 cells that contain the PIK3CA H1047R activating mutation shown to be associated with decreased pathological complete response in HER2 breast cancer patients treated with combined trastuzumab and lapatinib [56] and increased resistance to HER2-targeting drugs [18].